Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.~Exclusion Criteria:~* Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer.~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance.~* With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study.~* Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).